Skip to main content

Month: March 2022

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Advanced programs across NGM Bio’s pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022:Obtained Fast Track designation from the U.S. Food and Drug Administration (FDA) for NGM621, an anti-complement C3 antibody product candidate, for the treatment of patients with geographic atrophy (GA) secondary to age-related macular degeneration Completed enrollment in the Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated NASH cirrhosis (F4 NASH), with topline data expected in the first half of 2023$366.3 million in cash, cash equivalents and marketable securities as of December 31, 2021  SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM),...

Continue reading

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent EventsInitiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis in the fourth quarter of 2021. Reported topline data from ENIGMA 2, a Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with eosinophilic gastritis/eosinophilic duodenitis (“EG”/“EoD”) in the fourth quarter of 2021. Reported topline data from KRYPTOS, a Phase 2/3 randomized, double-blind,...

Continue reading

MARTEN TRANSPORT ANNOUNCES DIVIDEND INCREASE

MONDOVI, Wis., March 01, 2022 (GLOBE NEWSWIRE) —  Marten Transport, Ltd. (Nasdaq/GS:MRTN) announced today that its Board of Directors has declared a 50% increase in the Company’s regular quarterly cash dividend to $0.06 per share of common stock from $0.04 per share, beginning with the dividend payable on March 31, 2022 to stockholders of record at the close of business on March 17, 2022. This is Marten’s 47th consecutive quarterly cash dividend. With the payment of this dividend, Marten will have paid a total of $198.0 million in cash dividends, including special dividends totaling $134.9 million in 2021, 2020, 2019 and 2012, since the dividend program was implemented in the third quarter of 2010. Marten Transport, with headquarters in Mondovi, Wis., is a multifaceted business offering a network of refrigerated and dry truck-based...

Continue reading

HealthEquity Sets Date to Announce FY22 Results

Presentation at Conference DRAPER, Utah, March 01, 2022 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest independent health savings account (“HSA”) non-bank custodian, today announced plans to release its fiscal year-end financial results following the close of regular stock market trading hours on Tuesday, March 22, 2022. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, March 22, 2022, at 4:30 pm ET during which management will review the Company’s fourth quarter and fiscal January 31, 2022, year-end results.HealthEquity Fiscal Year 2022 Results Conference CallDate: March 22, 2022Time: 4:30 p.m. Eastern Time / 2:30 p.m. Mountain TimeDial-In: 1-844-791-6252 (US and Canada) 1-661-378-9636 (International)Conference...

Continue reading

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET. A live audio webcast of the fireside chat will be available under “Events & Presentations” in the Investor Relations section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation. About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the...

Continue reading

Sprouts Farmers Market to Present at the UBS Global Consumer & Retail Conference

PHOENIX, March 01, 2022 (GLOBE NEWSWIRE) — Sprouts Farmers Market, Inc. (Nasdaq: SFM) today announced the Company’s participation in the UBS Global Consumer and Retail Conference. Jack Sinclair, Chief Executive Officer and Chip Molloy, Chief Financial Officer, are scheduled to conduct a fireside chat discussion at 9:00 AM EST on March 10, 2022. A live webcast of the fireside chat will be available on the Investor Relations section of the Company’s website at investors.sprouts.com. About Sprouts Farmers Market Sprouts is the place where goodness grows. True to its farm-stand heritage, Sprouts offers a unique grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspires wellness naturally with a carefully curated assortment of better-for-you products paired with purpose-driven people....

Continue reading

Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging Interim Data Reported from Phase 2 Study of ANX005 for Huntington’s Disease; Full Data Expected in the Second Quarter of 2022 $243 Million in Cash and Investments at End of 2021; Operating Runway into First Quarter of 2024 BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced recent highlights and reported fourth quarter and full year 2021 financial results. “2021 was a year of marked progress across our pipeline, which is uniquely designed to provide greater protection against complement-mediated...

Continue reading

MasterCraft to Participate in Raymond James 43rd Annual Institutional Investors Conference

VONORE, Tenn., March 01, 2022 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) (the “Company”) today announced that Fred Brightbill, MasterCraft’s Chief Executive Officer, Tim Oxley, Chief Financial Officer, and George Steinbarger, Chief Revenue Officer, will present at the Raymond James 43rd Annual Institutional Investors Conference, presented in-person and virtually, on Monday, March 7, 2022, at 11:00 a.m. EST. A live audio webcast of the conference presentation will be available on MasterCraft’s website at http://investors.mastercraft.com/events-and-presentations/upcoming-events. The archived webcast will remain posted on the Company’s investor relations website for 30 days. About MasterCraft Boat Holdings, Inc.Headquartered in Vonore, Tenn., MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) is a leading...

Continue reading

Plug Power Announces 2021 Fourth Quarter Results

LATHAM, N.Y., March 01, 2022 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a leading provider of turnkey hydrogen solutions for the global green hydrogen economy, has announced today its 2021 fourth quarter results. The quarterly shareholder letter has been posted at https://www.ir.plugpower.com/Q421Plug. A conference call will be held today, March 1, 2022.Time: 4:30 pm ET Toll-free: 877-405-1239; 201-389-0851 Direct webcast: https://event.webcasts.com/starthere.jsp?ei=1531115&tp_key=cd5b4b33b7Both the shareholder letter and webcast can be accessed at www.plugpower.com, on the company’s home and investor relations pages. A playback of the call will be available online for a period following the event. About Plug Power Inc.          Plug Power is building the hydrogen economy as the leading provider of comprehensive...

Continue reading

Better Choice Company to Participate in Upcoming Investor Conferences in March 2022

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) — Better Choice Company (NYSE American: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced management’s participation in three upcoming March 2022 investor conferences. DA Davidson 5th Annual Consumer Growth Conference Virtually, March 10, 2022Donald Young & Ryan Wilson to present on Thursday, March 10th at 8:45 a.m. ETTo register, please visit the event website ROTH Capital Partners 34th Annual Conference In person, March 13-15, 2022 The Ritz Carlton Laguna Niguel Hotel, Dana Point, CAScott Lerner & Robert Sauermann to present on Monday, March 14th at 9:30 a.m. ET Webcast: https://wsw.com/webcast/roth43/bttr/1846896To register, please visit the event website Management will be available during the events for 1×1...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.